Label: FACTREL- gonadorelin hydrochloride injection

  • NDC Code(s): 54771-4311-1, 54771-4311-2
  • Packager: Zoetis Inc.
  • Category: PRESCRIPTION ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated December 28, 2016

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    50 mcg gonadorelin per mL (as gonadorelin hydrochloride) Solution for Intramuscular Injection.

    For use in cattle only

  • CAUTION

    Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION

    FACTREL Injection is a sterile solution containing 50 micrograms of synthetic gonadorelin (as hydrochloride) per mL in aqueous formulation containing 0.6% sodium chloride and 2% benzyl alcohol (as a preservative).

    Gonadorelin is the gonadotropin releasing hormone (GnRH) which is produced by the hypothalamus and causes the release of the gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary.

    FACTREL Injection has the identical amino acid sequence as endogenous gonadorelin; 5-oxo Pro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 with identical physiological activities. The molecular weight of gonadorelin is 1182 with a molecular formula of C55H75N17O13. The corresponding values for gonadorelin hydrochloride are 1219 (1 HCl) expressed as C55H75N17O13HCl, or 1255 (2 HCl) expressed as C55H75N17O13 2HCl.

  • INDICATIONS FOR USE

    For the treatment of ovarian follicular cysts in lactating dairy cows, beef cows, and replacement dairy and beef heifers. The treatment effect of FACTREL Injection when used in lactating dairy cows, beef cows, and replacement dairy and beef heifers is a reduction in the number of days to first estrus.

    For use with LUTALYSE® (dinoprost tromethamine injection) Injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows.

  • DOSAGE

    For the treatment of ovarian follicular cysts in lactating dairy cows, beef cows, and replacement dairy and beef heifers: Administer 2 mL of FACTREL Injection as a single intramuscular injection.

    For use with LUTALYSE (dinoprost tromethamine injection) Injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows: Administer 2 to 4 mL FACTREL Injection (100-200 mcg gonadorelin) per cow as an intramuscular injection in a treatment regimen with the following framework:

    • Administer the first dose of FACTREL Injection (2-4 mL) at Day 0

    • Administer LUTALYSE (25 mg dinoprost, as dinoprost tromethamine  injection) Injection by intramuscular injection 6-8 days after the     first dose of FACTREL Injection.

    • Administer a second dose of FACTREL Injection (2-4 mL) 30 to 72 hours after the LUTALYSE injection.

    • Perform FTAI 0 to 24 hours after the second dose of FACTREL Injection, or inseminate cows on detected estrus using standard herd     practices.

    Below are three examples of  treatment regimens for FTAI that fit within the dosage regimen framework described immediately above:

    NA

    Example 1

    Example 2

    Example 3

    Day 0

    (Monday)

    1st FACTREL

    1st FACTREL

    1st FACTREL

    Day 7 (the following

    Monday)

    LUTALYSE

    LUTALYSE

    LUTALYSE

    Day 9

    (Wednesday)

    2nd FACTREL

    + FTAI at

    48 hours after

    LUTALYSE

    2nd FACTREL

    48 hours after

    LUTALYSE

    2nd FACTREL

    56 hours after

    LUTALYSE

    Day 10

    (Thursday)

    NA

    FTAI

    24 hours after

    2nd FACTREL

    FTAI

    18 hours after

    2nd FACTREL


  • MECHANISM OF ACTION

    Follicular cysts are enlarged non-ovulatory follicles resulting from a malfunction of the neuroendocrine mechanism controlling follicular maturation and ovulation. Exogenous administration of agents possessing luteinizing hormone (LH) activity, such as pituitary extracts or human chorionic gonadotropin, often causes ovulation or regression of follicular cysts. FACTREL Injection induces release of endogenous luteinizing hormone (LH) to produce this same effect.

    Gonadorelin, through release of LH has been demonstrated to induce ovulation of dominant ovarian follicles present on the bovine ovary during the estrous cycle. Administration of FACTREL Injection has the same effect.

  • WARNINGS AND PRECAUTIONS

    For use in animals only. Not for human use. Keep out of reach of children.

  • RESIDUE WARNINGS

    No withdrawal period or milk discard time is required when used according to labeling.

  • EFFECTIVENESS

    For the treatment of ovarian follicular cysts in lactating dairy cows, beef cows, and replacement dairy and beef heifers:

    The treatment effect of FACTREL Injection when used in lactating dairy cows, beef cows, and replacement dairy and beef heifers is a reduction in the number of days to first estrus.

    There were no significant differences in days from treatment to conception, frequency of cows conceiving at first or subsequent heats, or conception rates among treated or non-treated control animals, when FACTREL Injection was used alone for treatment of cystic ovaries.

    For use with LUTALYSE (dinoprost tromethamine injection) Injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows:

    A field study was conducted to compare control (0 mL FACTREL Injection) to two doses of 2, 3 or 4 mL FACTREL Injection (100-200 mcg gonadorelin) for use with LUTALYSE Injection to synchronize estrous cycles to allow FTAI in lactating dairy cows under field conditions. Cows were examined prior to study start and only clinically normal cows were enrolled. A total of 1142 cows were enrolled at 6 commercial dairies. Cows were assigned randomly in blocks of 4 cows to each of 4 treatment groups consisting of:

                  Day 0: 2, 3 or 4 mL dose of FACTREL Injection or no injection (Control)

                  Day 7: 5 mL LUTALYSE Injection (all treatment groups)

                  Day 9: 2, 3 or 4 mL dose of FACTREL Injection or no injection (Control)

                  Day 10: Fixed-time artificial insemination

    On Day 9 the second dose of FACTREL Injection (cows received the same dose as for first treatment) was given either 48 or 56 hours after the dose of LUTALYSE Injection and FTAI was conducted 24 or 17 hours later, respectively. For control cows FTAI was performed 72 hours after the LUTALYSE Injection dose was administered. All treatment groups had significantly greater pregnancy rates to FTAI than cows administered LUTALYSE Injection alone, and were 17.1, 27.3, 29.1 and 32.2% for cows receiving 0 (Control), 2, 3 or 4 mL FACTREL Injection, respectively.

    .

  • SAFETY AND TOXICITY

    In cows the intramuscular administration of up to 12.5 times maximum recommended dosage (2,500 mcg/day) of FACTREL Injection for 3 days did not affect any physiological or clinical parameter. Likewise, single intramuscular doses of 500 mcg did not interfere with pregnancy. No evidence of irritation at injection site was found in any animal.

    A total of 1142 cows were enrolled in the previously noted field study that evaluated the effectiveness of two doses of 2, 3 or 4 mL of FACTREL Injection for use with LUTALYSE Injection to synchronize estrous cycles to allow FTAI in lactating dairy cows. Cows were observed daily for abnormal clinical signs. Over the course of the study there were 148 adverse health events documented in 118 cows. These adverse health events were common conditions in dairy cows (mastitis, lameness and pneumonia) and are not considered related to treatment.

  • ADVERSE REACTIONS

    To report suspected adverse events, for technical assistance or to obtain a copy of the Material Safety Data Sheet (MSDS) contact Zoetis Inc. at 1-888-963-8471.

    For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

  • HOW SUPPLIED

    FACTREL Injection (gonadorelin injection), 50 mcg/mL is available in 20 mL and 50 mL multi-dose vials (box of one).

  • Storage Conditions

    Store at refrigerator temperature 2° to 8°C (36° to 46°F). Use contents within 1 month of first vial puncture.

    NADA 139-237, Approved by FDA

    Distributed by:

    Zoetis Inc.

    Kalamazoo, MI 49007

    Revised: May 2015     40004714

  • PRINCIPAL DISPLAY PANEL - 20 mL Bottle Carton

    Factrel® Injection
    (gonadorelin injection)
    50 mcg gonadorelin per mL

    Solution for
    Intramuscular Injection

    For use in cattle only

    Net Content: 20 mL

    CAUTION: Federal (USA) law
    restricts this drug to use by or
    on the order of a licensed veter-
    inarian.

    NADA 139-237, Approved by FDA

    Zoetis

    Factrel 20 mL Carton Label
  • PRINCIPAL DISPLAY PANEL - 50 mL Bottle Carton

    Factrel® Injection
    (gonadorelin injection)
    50 mcg gonadorelin per mL

    Solution for
    Intramuscular Injection

    For use in cattle only

    Net Content: 50 mL

    CAUTION: Federal (USA) law
    restricts this drug to use by or
    on the order of a licensed veter-
    inarian.

    NADA 139-237, Approved by FDA

    Zoetis

    Factrel 50 mL Carton Label
  • INGREDIENTS AND APPEARANCE
    FACTREL 
    gonadorelin hydrochloride injection
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:54771-4311
    Route of AdministrationINTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    GONADORELIN HYDROCHLORIDE (UNII: 3PFC574ITA) (GONADORELIN - UNII:9O7312W37G) GONADORELIN50 ug  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZYL ALCOHOL (UNII: LKG8494WBH)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:54771-4311-11 in 1 CARTON
    120 mL in 1 VIAL, MULTI-DOSE
    2NDC:54771-4311-21 in 1 CARTON
    250 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA13923703/01/2014
    Labeler - Zoetis Inc. (828851555)